Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma.
Open Access
- 25 June 2020
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (4), 1172-1177
- https://doi.org/10.3324/haematol.2019.244418
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Acidosis and proteolysis in the tumor microenvironmentCancer and Metastasis Reviews, 2019
- A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alterationOncotarget, 2016
- Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal nicheNature Communications, 2015
- Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvateJournal of Bioenergetics and Biomembranes, 2012
- Osteoclast‐targeting small molecules for the treatment of neoplastic bone metastasesCancer Science, 2009
- Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeuticsMolecular Cancer Therapeutics, 2006
- Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclastsProceedings of the National Academy of Sciences of the United States of America, 2006
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- Bone Resorption by OsteoclastsScience, 2000
- Acid pH in tumors and its potential for therapeutic exploitation.1989